Melmark Taps Pharma, Tech Titans for Board in Strategic Power Play

ANDOVER, MA – January 27, 2026 – As it celebrates its 60th anniversary, Melmark, a leading non-profit provider of services for individuals with autism and intellectual disabilities, has fortified its leadership with two high-profile appointments to its Board of Directors. The addition of Dr. Howard Mayer, a pharmaceutical research and development veteran, and Amanda Westphal Radcliffe, a tech industry founder and billionaire philanthropist, signals a strategic move to blend top-tier corporate expertise with a profound personal commitment to its mission.

A Strategic Infusion of Corporate and Scientific Acumen

The appointments bring a formidable wealth of experience from sectors not typically associated with human services governance. Dr. Howard Mayer’s career is a distinguished tour of the pharmaceutical industry's leading firms. As the former Executive Vice President and Head of Research and Development at Ipsen Pharmaceuticals, and with past leadership roles at Shire, EMD Serono, and Pfizer, he has overseen clinical development on a global scale. Critically, his time at Pfizer included being a founding member of its Autism Research Unit, giving him unique insight into the scientific underpinnings of the very conditions Melmark addresses.

Ms. Amanda Westphal Radcliffe brings a different but equally potent skill set. As a founding family member of the global tax technology company Vertex Inc., she has over 30 years of board experience, where she was instrumental in guiding the company’s transition from a private family business to a publicly traded entity in 2020. Her expertise in corporate governance, finance, and scaling a technology-focused enterprise aligns directly with the evolving needs of the modern non-profit sector. This background is particularly relevant as organizations like Melmark look to leverage technology, such as its own EnvisionSMART™ platform, to enhance service delivery and operational efficiency.

These appointments come as Melmark implements a five-year strategic plan established in 2022. The plan emphasizes enhancing its evidence-based clinical models, investing in workforce development, and expanding its reach. The combined expertise of Mayer and Radcliffe is poised to directly fuel these ambitions. Dr. Mayer's clinical and regulatory knowledge can inform the refinement of Melmark's services, which are based on the principles of Applied Behavior Analysis (ABA), while Ms. Radcliffe’s experience in corporate growth and technology can help the organization navigate expansion and innovate in a sector facing significant workforce and funding challenges.

“We are thrilled to welcome Dr. Howard Mayer and Ms. Amanda Radcliffe to our Board of Directors,” stated Melmark President and CEO Rita M. Gardner. “Howard and Amanda are passionate and committed to supporting and enhancing the lives of individuals within diverse communities with autism, intellectual and developmental disabilities, and their families. The addition of these two outstanding leaders to our board brings valuable perspective and expertise that will advance our mission and vision.”

Beyond the Boardroom: The Power of Personal Commitment

What makes these appointments particularly powerful is that both Dr. Mayer and Ms. Radcliffe are parents of individuals served by Melmark. This personal connection transforms their roles from a matter of professional oversight to one of deep, personal investment. Dr. Mayer and his family have been part of the Melmark community for over a decade, while Ms. Radcliffe is also a dedicated Melmark parent. This lived experience is increasingly seen as a best practice in non-profit governance, ensuring that the needs of families and individuals served remain at the heart of every strategic decision.

Their personal commitment is further evidenced by their extensive philanthropic work in the neurodiversity and disability space. Dr. Mayer has served on the board of Autism Speaks in New England since 2011, lending his professional expertise to advocacy and research. Ms. Radcliffe’s philanthropic footprint is immense; she is the founding President of the Neurodiversity Employment Network of Philadelphia and serves on advisory boards for the Kinney Center for Autism Education and Support at St. Joseph's University and The Precisionists. Her work demonstrates a long-standing dedication to creating inclusive opportunities and support systems for neurodivergent individuals, extending far beyond her family’s direct needs.

This blend of high-level professional skill and authentic personal connection creates a powerful synergy on the board. It ensures that discussions about financial sustainability, strategic expansion, and clinical efficacy are always grounded in the real-world impact on the more than 600 individuals Melmark serves across its divisions in Pennsylvania, New England, and the Carolinas.

60 Years Strong: A Legacy Attracting Top Talent

For an organization to attract a twice-recognized “Most Inspiring Person in the Life Sciences Industry” and a Forbes-listed billionaire to its board is a testament to its own standing and impact. Melmark’s ability to secure such leaders during its 60th anniversary year underscores the strength of its reputation, built over six decades of providing clinically sophisticated services for individuals with complex needs. It operates in a challenging environment, where human services providers grapple with workforce shortages and funding crises. In this context, attracting and retaining top-tier volunteer leadership is crucial for long-term stability and growth.

Melmark has a history of strategic growth, including the construction of a $19 million educational facility in Pennsylvania and the successful expansion of its services to the Carolinas. Its commitment to a “mission-first” approach and the replication of its evidence-based “Melmark Model of Program Development and Clinical Treatment” has positioned it as a national leader. The organization's explicit focus on Diversity, Equity, and Inclusion (DEI), embedded in its strategic plan and daily operations, further demonstrates a commitment to modern, equitable, and culturally competent care.

The appointments of Dr. Mayer and Ms. Radcliffe are not merely additions; they are a clear statement of intent. By bringing in leadership with proven track records in scientific innovation, corporate strategy, and profound personal dedication, Melmark is positioning itself not just to navigate the challenges of the next decade, but to lead the way in transforming the landscape of disability services.